Thiotepa

Peroxisomal Disorders

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

7 Active assets in the Peroxisomal Disorders cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Masonic Cancer Center, University of Minnesota	Phase 2	B
Busulphan Masonic Cancer Center, University of Minnesota	Phase 2	B
Fludarabine Masonic Cancer Center, University of Minnesota	Phase 2	B
Romidepsin Masonic Cancer Center, University of Minnesota	Phase 2	B
CHOLALIC ACID Mirum Pharmaceuticals, Inc.	Phase 3	B